Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,944,434 papers from all fields of science
Search
Sign In
Create Free Account
ocrelizumab
Known as:
rhuMAb 2H7
A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (1)
Antibodies, Monoclonal, Humanized
NCIt Antineoplastic Agent Terminology
antigen binding
Narrower (1)
PR 070769
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design (P3.2-091)
G. Giovannoni
,
L. Airas
,
+11 authors
J. Wolinsky
2019
Corpus ID: 199615557
Objective: To assess ocrelizumab efficacy on upper limb function in more disabled/older patients with primary progressive…
Expand
2018
2018
New Inroads Against Multiple Sclerosis.
J. Lyon
Journal of the American Medical Association (JAMA…
2018
Corpus ID: 7780701
Review
2018
Review
2018
New biological agents in the treatment of multiple sclerosis.
M. Buc
Bratislava Medical Journal
2018
Corpus ID: 4900642
Multiple sclerosis (MS) is an inflammatory disease induced by autoimmune processes. Their understanding has resulted in an…
Expand
Review
2017
Review
2017
McDonald Criteria . a Acute Exacerbation History MRI History Additional Data Needed 2 Exacerbations 2 Lesions None 2 Exacerbations 1 Lesion
Amanda M. Stahnke
,
K. Holt
2017
Corpus ID: 207786626
Multiple sclerosis (MS) is an autoimmune, neurodegenerative disorder of the central nervous system that affects nearly 2.5…
Expand
2015
2015
CETP set-back, again
Asher Mullard
Nature reviews. Drug discovery
2015
Corpus ID: 28735345
as possible MS agents for years. Roche’s first-in-class CD20-binding rituximab yielded promising signs of efficacy in MS, but…
Expand
2015
2015
Roche hits multiple sclerosis landmarks
Asher Mullard
Nature reviews. Drug discovery
2015
Corpus ID: 1839946
2015
2015
News from the ECTRIMS Annual Meeting: Ocrelizumab Reported to be Effective Against MS in Three Trials
E. Susman
2015
Corpus ID: 75442331
BARCELONA—Ocrelizumab was reportedly effective in reducing the risk of multiple sclerosis (MS) relapse in two phase 3 trials…
Expand
2012
2012
Drugs in Clinical Development for Multiple Sclerosis
Pharmaceutical Medicine
2012
Corpus ID: 17122112
and Table Multiple sclerosis (MS) is an autoinflammatory neuro-degenerative disorder of the protective myelin component of the…
Expand
Review
2009
Review
2009
Neue Anti-B-Zell-Strategien für die Therapie rheumatischer Erkrankungen
Dr. I.H. Tarner
Zeitschrift für Rheumatologie (Print)
2009
Corpus ID: 25120515
ZusammenfassungDer klinische Erfolg der Depletierung von B-Zellen durch den Anti-CD20-Antikörper Rituximab hat eine neue Ära in…
Expand
2009
2009
FIXED SINGLE INJECTION DOSAGE FOR OCRELIZUMAB (2H7) FIELD OF THE INVENTION The invention relates to the treatment of autoimmune diseases, including rheumatoid arthritis, by administration of a CD20…
2009
Corpus ID: 59491945
(51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) A61P…
Expand